KeyBank National Association’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.33M Buy
2,132
+69
+3% +$47K ﹤0.01% 565
2026
Q1
$1.59M Buy
2,063
+388
+23% +$297K 0.01% 498
2025
Q4
$1.29M Buy
1,675
+94
+6% +$63.8K ﹤0.01% 528
2025
Q3
$889K Buy
1,581
+148
+10% +$83.7K ﹤0.01% 608
2025
Q2
$752K Sell
1,433
-100
-7% -$55.8K ﹤0.01% 645
2025
Q1
$972K Buy
1,533
+294
+24% +$202K ﹤0.01% 559
2024
Q4
$883K Buy
1,239
+76
+7% +$63.8K ﹤0.01% 590
2024
Q3
$1.22M Buy
1,163
+134
+13% +$149K ﹤0.01% 514
2024
Q2
$1.08M Buy
1,029
+10
+1% +$9.69K ﹤0.01% 518
2024
Q1
$981K Buy
1,019
+67
+7% +$63.7K ﹤0.01% 537
2023
Q4
$836K Buy
952
+35
+4% +$28.8K ﹤0.01% 577
2023
Q3
$755K Sell
917
-20
-2% -$15.7K ﹤0.01% 552
2023
Q2
$673K Buy
937
+5
+0.5% +$3.85K ﹤0.01% 603
2023
Q1
$766K Sell
932
-52
-5% -$39.2K ﹤0.01% 542
2022
Q4
$710K Buy
984
+85
+9% +$62.7K ﹤0.01% 558
2022
Q3
$619K Sell
899
-10
-1% -$6.29K ﹤0.01% 584
2022
Q2
$537K Buy
909
+145
+19% +$94.3K ﹤0.01% 639
2022
Q1
$534K Sell
764
-105
-12% -$66.4K ﹤0.01% 698
2021
Q4
$549K Buy
869
+47
+6% +$28.9K ﹤0.01% 776
2021
Q3
$497K Buy
822
+233
+40% +$145K ﹤0.01% 796
2021
Q2
$329K Buy
589
+75
+15% +$38K ﹤0.01% 921
2021
Q1
$243K Sell
514
-180
-26% -$87.6K ﹤0.01% 987
2020
Q4
$335K Buy
694
+40
+6% +$21.6K ﹤0.01% 875
2020
Q3
$366K Buy
654
+215
+49% +$130K ﹤0.01% 783
2020
Q2
$274K Sell
439
-448
-51% -$254K ﹤0.01% 833
2020
Q1
$433K Buy
887
+92
+12% +$37.9K ﹤0.01% 661
2019
Q4
$299K Sell
795
-21
-3% -$7.07K ﹤0.01% 858
2019
Q3
$226K Sell
816
-39
-5% -$11.5K ﹤0.01% 910
2019
Q2
$268K Sell
855
-55
-6% -$18.3K ﹤0.01% 898
2019
Q1
$374K Sell
910
-68
-7% -$28K ﹤0.01% 778
2018
Q4
$365K Sell
978
-1,664
-63% -$609K ﹤0.01% 739
2018
Q3
$1.07M Buy
2,642
+73
+3% +$27.8K 0.01% 532
2018
Q2
$886K Buy
2,569
+1,255
+96% +$393K 0.01% 588
2018
Q1
$452K Buy
1,314
+37
+3% +$12.9K ﹤0.01% 775
2017
Q4
$480K Sell
1,277
-988
-44% -$400K ﹤0.01% 760
2017
Q3
$1.01M Sell
2,265
-9
-0.4% -$4.28K 0.01% 552
2017
Q2
$1.12M Buy
2,274
+68
+3% +$29.8K 0.01% 551
2017
Q1
$855K Sell
2,206
-49
-2% -$18.2K 0.01% 660
2016
Q4
$828K Buy
2,255
+70
+3% +$26.6K 0.01% 665
2016
Q3
$878K Buy
2,185
+278
+15% +$112K 0.01% 641
2016
Q2
$666K Sell
1,907
-1,028
-35% -$396K ﹤0.01% 684
2016
Q1
$1.06M Buy
2,935
+47
+2% +$19.4K 0.01% 521
2015
Q4
$1.57M Buy
2,888
+41
+1% +$22.2K 0.01% 414
2015
Q3
$1.32M Buy
2,847
+311
+12% +$167K 0.01% 474
2015
Q2
$1.29M Sell
2,536
-19
-0.7% -$9.27K 0.01% 525
2015
Q1
$1.15M Sell
2,555
-70
-3% -$29.7K 0.01% 578
2014
Q4
$1.08M Buy
2,625
+116
+5% +$45.6K 0.01% 593
2014
Q3
$905K Sell
2,509
-3,091
-55% -$1.04M 0.01% 655
2014
Q2
$1.58M Buy
5,600
+523
+10% +$155K 0.01% 496
2014
Q1
$1.52M Sell
5,077
-899
-15% -$277K 0.01% 500
2013
Q4
$1.65M Sell
5,976
-82
-1% -$23.6K 0.01% 477
2013
Q3
$1.9M Sell
6,058
-865
-12% -$228K 0.01% 407
2013
Q2
$1.56M Buy
+6,923
New +$1.61M 0.01% 686

Other funds holding REGN

KeyBank National Association's REGN Position: Q2 2026 in Review

KeyBank National Association increased its Regeneron Pharmaceuticals (REGN) stake by 3.3% in Q2 2026, buying an estimated $47K and bringing the position to 2,132 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #565.

KeyBank National Association first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.9M in Q3 2013. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • KeyBank National Association held 2,132 shares of Regeneron Pharmaceuticals worth $1.33M as of Q2 2026.
  • KeyBank National Association bought 69 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $47K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #565 holding.
  • KeyBank National Association first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • KeyBank National Association's Regeneron Pharmaceuticals position peaked at $1.9M in Q3 2013.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.